Table 2.

Multivariate analysis

VariableHR95% CIP valueSignificance level
Post-HCT AUC of ATG (continuous)     
 CD4+ IR 0.974 0.962-0.986 <.0001 **** 
 EFS 1.005 1.001-1.009 .0071 ** 
 OS 1.005 1.001-1.009 .026 * 
 NRM 1.005 1.001-1.009 .028 * 
Use of ATG (no ATG is reference)     
 Acute GVHD grade 2-4 0.878 0.353-2.185 .78  
 Acute GVHD grade 3-4 0.268 0.083-0.862 .027 * 
 Chronic extensive GVHD 1.132 0.137-9.383 .91  
IR (no IR is reference)     
 EFS 0.264 0.156-0.447 <.0001 **** 
 OS 0.516 0.279-0.955 .035 * 
 NRM 0.358 0.154-0.829 .017 * 
 RRM in myeloid leukemia 0.134 0.03-0.595 .008 ** 
VariableHR95% CIP valueSignificance level
Post-HCT AUC of ATG (continuous)     
 CD4+ IR 0.974 0.962-0.986 <.0001 **** 
 EFS 1.005 1.001-1.009 .0071 ** 
 OS 1.005 1.001-1.009 .026 * 
 NRM 1.005 1.001-1.009 .028 * 
Use of ATG (no ATG is reference)     
 Acute GVHD grade 2-4 0.878 0.353-2.185 .78  
 Acute GVHD grade 3-4 0.268 0.083-0.862 .027 * 
 Chronic extensive GVHD 1.132 0.137-9.383 .91  
IR (no IR is reference)     
 EFS 0.264 0.156-0.447 <.0001 **** 
 OS 0.516 0.279-0.955 .035 * 
 NRM 0.358 0.154-0.829 .017 * 
 RRM in myeloid leukemia 0.134 0.03-0.595 .008 ** 

* <.05; ** <.01; *** <.001; **** <.0001.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal